<DOC>
	<DOCNO>NCT01945021</DOCNO>
	<brief_summary>To assess treatment effectiveness safety oral crizotinib administer East Asian patient Advanced Non-Small Cell Lung Cancer ( NSCLC ) confirm positive ROS1 positive gene mutation ( translocation inversion ) confirm negative ALK mutation</brief_summary>
	<brief_title>Phase II Safety Efficacy Study Crizotinib East Asian Patients With ROS1 Positive , ALK Negative Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically proven diagnosis NSCLC locally advance metastatic treatmentna√Øve receive 3 systemic treatment regimen ( ) Positive translocation inversion event involve ROS1 gene Negative translocation inversion event involve ALK gene Patients brain metastasis eligible asymptomatic , treated , must neurologically stable least 2 week take contraindicated medication Any prior treatment ( chemotherapy , radiation [ except palliative ] , surgery ) must complete least 2 week prior initiation study medication At least 1 measurable tumor lesion per RECIST v1.1 Female male , 18 year age old ECOG performance status 0 1 Adequate organ function Signed date informed consent Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure , include completion PRO measure Agree use effective contraception study period least 90 day completion study treatment Current treatment another therapeutic clinical trial Prior therapy specifically direct ALK ROS1 fusion gene Spinal cord compression unless treat patient attain good pain control stable recover neurologic function , carcinomatous meningitis , leptomeningeal disease know interstitial fibrosis interstitial lung disease myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident include transient ischemic attack within 3 month prior start study treatment Ongoing cardiac dysrhythmias NCI CTCAE v4.03 Grade &gt; /=2 , uncontrolled atrial fibrillation grade , QTc &gt; 470 msec Pregnant breast feeding Use drug food know potent CYP3A4 inhibitor inducer Use anticancer drug include traditional Chinese medicine SFDA list Evidence active malignancy within last 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>ROS1</keyword>
	<keyword>ROS1 positive</keyword>
	<keyword>ROS1 proto oncogene</keyword>
	<keyword>c ros tyrosine kinase</keyword>
	<keyword>ROS1 positive NSCLC</keyword>
	<keyword>ROS1 lung cancer</keyword>
	<keyword>ALK negative</keyword>
	<keyword>Lung Carcinoma</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Crizotinib</keyword>
	<keyword>Xalkori</keyword>
	<keyword>Previously treat untreated</keyword>
	<keyword>North East Asian</keyword>
</DOC>